| Name | Title | Contact Details |
|---|
Founded in 2006, Ocular Therapeutix is a fast-growing, aspiring leader in the biopharmaceutical industry. The company has a clear vision – to improve current therapeutic options in ophthalmology by encapsulating previously approved therapeutic agents in our novel hydrogel to provide a sustained delivery of drugs to the eye. We are reframing the industry with new modalities for ophthalmic therapies. As a small company, our employees are provided the unique opportunity to help build the foundation of the business as it grows. We strongly believe that our success is contingent upon the achievements of our employees. We strive to create a collaborative, challenging environment that encourages individuals to bring success to their career and the company. Through the use of our proprietary hydrogel technology, we strive to offer superior products that improve the world’s vision.
Bovie Medical Corporation is a leading maker of medical devices and supplies as well as the developer of J-Plasma®, a patented new plasma-based surgical product for cutting and coagulation. J-Plasma® utilizes a helium ionization process to produce a stable, focused beam of ionized gas that provides surgeons with greater precision, minimal invasiveness and an absence of conductive currents through the patient during surgery. Bovie Medical Corporation is also a leader in the manufacture of a range of electrosurgical products and technologies, marketed through both private labels and the Company`s own well-respected brands (Bovie®, Aaron®, IDS™ and ICON™) to distributors worldwide. The Company also leverages its expertise through original equipment manufacturing (OEM) agreements with other medical device manufacturers.
American Medical Depot is a Opa Locka, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Oncologix is a diversified medical device and healthcare holding company. For its customers, Oncologix provides FDA approved medical devices and state licensed healthcare services. For its shareholders, Oncologix acquires profitable operations that build, maintain and nourish shareholder value. The Company`s corporate mission is to be the best small cap medical device and healthcare holding company in North America.
Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company`s focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it a leading cause of death in the U.S. Approximately 1.7 million Americans have AAA, and the incidence of the condition increases with age. Endologix is currently marketing the AFX® Endovascular AAA System is available in the U.S., Europe, Latin America and other regions. The Nellix® EndoVascular Aneurysm Sealing System, a novel aneurysm sealing system, is approved for sale in Europe and other markets and for investigational use in the U.S. The Powerlink with IntuiTrak® Delivery System is available in Japan. These technologies are minimally invasive, allowing for greater patient comfort and quicker recovery compared to invasive surgical alternatives. Endologix products are protected by at least 52 U.S. patents with at least 956 allowed claims. Endologix is a publicly-held company trading on NASDAQ: ELGX. The Company`s corporate office is located in Irvine, California.